Skip to main content

is part of the Informa Markets Division of Informa PLC

  • INFORMA PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Eurogin
 

December 2-5, 2018

Lisbon Portugal

  • 
  • Scientific Information
    • Welcome Message
    • Program Committee
    • Program Objectives
    • Program Topics
    • Instruction For Speakers
    • Key Features And Target Audience
    • Deadlines
    • Previous Congress Presidents
    • Previous Congresses
  • Program & CME
    • Final Scientific Program
    • Interactive Scientific Program
    • Program Overview
    • CME Credits
    • Workshop Lusófono
    • HPV And Head and Neck Forum
    • HPV Et Maladies Associees
    • Workshop Vulvar Diseases
    • Workshop Screening
    • Workshop HPV Immunization
    • Colposcopy Course
  • Registration
    • Online Registration
    • Registration Information
    • Eurogin Grants
  • Abstracts & Posters
    • Abstracts 2018
    • Abstract Information
    • Abstract Topics
    • Eurogin Grants
    • List of Posters
    • Poster Information
    • Official Poster Service
  • Sponsorship And Exhibition
    • Sponsorship Information
    • Sponsorship Brochure
    • Sponsors / Exhibitors
    • Ethicalmedtech
    • Exhibition Floorplan
    • Exhibitors Manual
  • Travel And Hotels
    • Travel Info
    • Congress Hotels
  • Congress Information
    • Information For French Participants
    • Supporting Partnerships
    • Practical Information
    • Program Book
    • Congress Venue
    • Opening Ceremony
    • Congress App Eurogin 2018
    • Contact
    • Legal Information
Previous
Next
  • Home
  • English
  • Program & CME
  • HPV And Head and Neck Forum

EUROGIN 2018 - INTERNATIONAL FORUM ON HPV AND HEAD & NECK CANCER

The EUROGIN HPV and Head and Neck Cancer Forum highlights areas of active investigation in the field of HPV and head and neck cancers. It offers a review of the current epidemiologic efforts which focus on the natural history of HPV infection, risk of transmission, screening for early cancer detection, and the potential impact of prophylactic HPV vaccines in the incidence of head and neck cancer, the role of HPV in benign and head and neck disease. The event evaluates how the differing biology of HPV-HNC leads to a re-assessment of clinical staging and clinical prognostic characteristics. Given the viral etiology of these tumors, sessions address to review immune evasion mechanisms utilized by HPV and the understanding of these mechanisms, with the hope of opening the path to novel immunotherapeutic strategies to reactivate the host immune response against the virus and virally-associated cancer cells.

A dedicated debate session will focus on the controversies regarding the impact of HPV infection on oro-pharyngeal cancer, including diagnosis, management and decision making.

Sunday, December 2: 08:30 - 17:00
Monday, December 3: 08:15 - 17:45

  • C. Fakhry (USA),
  • A. D'Souza (USA)
Session 1:
SUNDAY DECEMBER 2
8.30 – 10.00

Oral presentations 1

Chair: A. Psyrri

Session 2:
SUNDAY DECEMBER 2
10.30 – 12.00

Epidemiology of oral HPV infection

Chair: A. Giuliano

  • Natural history (focus upon known and unknown, how compares about cervical,   persistent infection, Vaccine)
    Dahlstrom K.
  • Sex differences
    Combes J-D
  • Tobacco and other risk factors
    D’Souza A.
  • Sampling of oral vs. tonsil
    Mirghani H.
Session 3:
SUNDAY DECEMBER 2
13.30 – 15.00

Recurrent metastatic HPV related cancer

Chair: P. Bossi

  • Epidemiologic changes: Aging population
    Windon M.
  • Biomarkers for detection of recurrence
    Agrawal N.
  • Molecular mechanisms below tumor response in HPV-related OPC, with a focus to locally advanced disease
    Welters M.
  • Response to immunotherapy in R/M orophayngeal cancer (OPC): comparing HPV-related and non HPV-related diseases
    Mesía R.
Session 4:
SUNDAY DECEMBER 2
15.30 – 17.00

Recurrent Respiratory Papillomatosis

Chair: S. Best

Recurrent Respiratory Papilloma (RRP) is a benign disease affecting the larynx of children and adults caused by infection with low-risk HPV 6 or 11. The need for recurrent surgery and its devastating effects on voice and breathing make treating this disease a great challenge. This session highlights recent developments in the epidemiology of RRP in the era of vaccination, the psychosocial impact of the disease, modern surgical treatment options, and the ongoing search for effective immunologic therapies.

  • Epidemiology, Incidence, and the Impact of Vaccination
    Friedman A.
  • Quality of Life and Psychosocial Effects in Patients with RRP
    San Giorgi M.
  • Office-based and Operating Room Treatment of papillomatosis
    Burns J.
  • Immune Polarization in RRP
    Best S.
  • Immunotherapy Trials in RRP
    Allen C.
Session 5:
MONDAY DECEMBER 3
8.15 – 9.45

Oral presentations 2

Chair: V. Mehta

Session 6:
MONDAY DECEMBER 3
9.45 – 11.15

HPV and non-oropharynx cancers

Chair: L. Mell

  • Larynx and oral cavity SCC (including P16 as a biomarker for HPV in non-oropharynx cancer)
    Taberna M.
  • Sinonasal cancers
    Rooper L.
  • Etiologic role of HPV in non-oropharynx cancers: global perspective
    Alemany L.
  • Prognostic implication of HPV in non-oropharynx cancer (p16 & hpv)
    Blanchard P.
Session 7:
MONDAY DECEMBER 3
14.15 – 15.45

Risk communication and screening for oral HPV mini-presentations and debate

Chair: A. D’souza

-How to screen?

  • Incidence of oropharynx cancer and risk groups with oral HPV and Serology to screen (15-20mins)
    D’Souza A.
  • Oral rinses (15-20mins)
    Giuliano A.
  • What does additional/ second screen look like and how intervene with suspicious? (15-20mins)
    Fakhry C.
  • When to screen? (Harms and benefits) When to test for HPV/p16 in HNSCC (15-20mins)
    Franceschi S.
  • Debate (and questions) (15-30 mins
    All speakers
Session 8:
MONDAY DECEMBER 3
16.15 – 17.45

New perspectives on the clinical care of oropharyngeal cancer

Chair: C. Fakhry

  • Staging and limitations of the standard of care
    Fakhry C.
  • The use of surgery for de-intensification
    Zevallos J.
  • De-intensification of radiotherapy
    Zumsteg Z.
  • The role of traditional adverse features in HPV-positive oropharynx cancer (ECS)
    Husain Z.
Session 9:
MONDAY DECEMBER 3
17.45 – 18.15

Oral presentations 3

Chair: TBD

  • Registration

    to EUROGIN congress 2019

  • ABSTRACT SUBMISSION DEADLINE

    August 27,  2019

  • PROGRAM

    2018 program overview

  • HPV AND HEAD & NECK FORUM

SPECIALIZED WORKSHOPS
  • HPV Immunization
  • Vulvar Diseases
  • Screening for Women Difficult to Reach
  • Advanced Colposcopy Course (Separate registration required)

  • WORKSHOP LUSÓFONO

ABOUT EUROGIN

EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) brings together clinicians and scientists whose work is related to genital infections and neoplasia.

NEWSLETTER

Subscribe to our newsletter

USEFUL LINKS

  • EUROGIN PORTAL |
  • Previous events |
  • Women Against Cervical Cancer |
  • HPV World |
  • Legal Information

SUPPORTED BY

TRUSTED PARTNER

Informa Markets

Copyright © 2022. All rights reserved. Informa Markets, a trading division of Informa PLC.

  • Accessibility|
  • Privacy Policy |
  • Cookie Policy|
  • Terms of Use|
  • Visitor Terms And Conditions